VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

NavnVRTXON

RangNo.3709

Markedscap$0.00

Fuldt udvandet markedsværdi$0.00

Markedsandel%

Handelsvolumen/markedsværdi (24H)0.00%

Cirkulationsforsyning0.35953858

Max Udbud0

Samlet Udbud0.35953858

Cirkulationshastighed%

Udstedelsesdato--

Den pris, som aktivet først blev udstedt til--

Alle tiders høj466.35223147502205,2026-03-26

Laveste pris432.04959348516377,2026-03-27

Offentlig blockchainETH

IndledningVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sektor

Social Media

• Officiel hjemmeside
• Bloker Explorer

etfindex:mc_etfindex_sourceAnsvarsfraskrivelse: Data leveret af cmc og bør ikke betragtes som investeringsrådgivning.